Clinical trials: Rectum Carcinoma
Radiotherapy, Radiation-Induced Complications
A Prospective, Single-Arm Clinical Study of a Dietary Supplement for the Prevention of Acute Radiation-Induced Rectal Injury During Neoadjuvant Chemoradiotherapy for Rectal Cancer
This clinical study is a prospective, single-arm, single-center trial aimed at assessing the safety and efficacy of tributyrin (TB) as a dietary supplement for preventing acute radiation-induced rectal injury (ARII).
- Trial name
- NCT07802002
- Testing
- Tributyrin
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00482222
- Testing
- cetuximab, capecitabine, fluorouracil
- Where
- 22 sites in United Kingdom
- Volunteers
- 340 people
- Sponsor
- University of Southampton
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
- Trial name
- NCT05544929
- Testing
- KFA115, pembrolizumab
- Where
- 18 sites in United States, Canada and 10 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Rectal Cancer, Low Anterior Resection Syndrome
Rectal Cancer Survivorship: Impact of Low Anterior Resection Syndrome (LARS) on the Quality of Life
Quality of life and risk factors for developing major LARS are explored. Therapeutic options were explored in the cohort experiencing major LARS
- Trial name
- NCT06059170
- Testing
- LARS score/ EORTC QLQ C30
- Where
- Belgium
- Volunteers
- 187 people
- Sponsor
- University Hospital, Ghent
Cervical Cancer, HPV Cancers
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
Background: More than 30,000 cases of human papillomavirus (HPV) associated cancers occur annually in the United States. When these cancers spread, they do not respond well to standard treatments and are often incurable.
- Conditions
- Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer
- Trial name
- NCT04287868
- Testing
- PDS0101, M7824, NHS-IL12
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: Vaccines may make the body build an immune response that will kill cancer cells. Combining vaccine therapy with interleukin-2 may kill more cancer cells.
- Trial name
- NCT00019591
- Testing
- aldesleukin, ras peptide cancer vaccine, adjuvant therapy
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Rectal Neoplasms, Rectal Cancer Stage II
Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer
Preoperative 5-FU-based (5-fluorouracil) chemoradiotherapy (CRT), total mesorectal excision surgery, and 4 cycles of adjuvant 5-FU - as established by CAO/ARO/AIO-94 - is at present a standard of care for patients with locally…
- Conditions
- Rectal Neoplasms, Rectal Cancer Stage II, Rectal Cancer Stage III
- Trial name
- CAOAROAIO-12 (NCT02363374)
- Testing
- Induction Chemotherapy arm A, Radiation arm A, Radiation arm B
- Where
- 20 sites in Germany
- Volunteers
- 311 people
- Sponsor
- Prof. Dr. med. Claus Rödel
Rectal Cancer
Total Mesorectum Excision With Left Colic Artery Preservation for the Treatment of Rectal Cancer
A randomized controlled clinical trial to compare the short and long term outcomes of left colic artery preservation for the treatment of Rectal Cancer
- Trial name
- NCT03724591
- Testing
- a high ligation of IMA, a low ligation of IMA
- Volunteers
- 600 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Colo-rectal Cancer
Erector Spinae Plane Block as Analgesia in Patients for Colectomy
Management of postoperative pain relief is largely inadequate. Despite the recent advances in pain management, postoperative pain incidence has not decreased; most patients still experience severe pain after major surgery.
- Trial name
- NCT06957574
- Testing
- Bubpivacaine
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Suez Canal University
Colo-rectal Cancer, Polygenic Risk Score
Development of Polygenic Risk Scores in Colon Cancer Patients Through the Study of Ancestry and Diversity in Genetic Maps of the Brazilian Population - ORIGEM Project
Development of a polygenic risk score based on somatic and germline genetic information from patients with colorectal cancer
- Conditions
- Colo-rectal Cancer, Polygenic Risk Score, Somatic Mutation, Hereditary Cancer
- Trial name
- ORIGEM (NCT06917794)
- Where
- 9 sites in Brazil
- Volunteers
- 500 people
- Sponsor
- D'Or Institute for Research and Education
Colon Cancer, Rectal Cancer
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as…
- Trial name
- SCOTI (NCT05806931)
- Testing
- TAS-102, oxaliplatin, irinotecan with bevacizumab
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Colorectal Cancer
Chemotherapy and Radiation Therapy Before Surgery Followed by Capecitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- PETACC-6 (NCT00766155)
- Testing
- capecitabine, oxaliplatin
- Volunteers
- 1,094 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II
"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
Pathologic complete response (pCR) after multimodal treatment for locally advanced rectal cancer (LARC) patients is considered as the gold-standard of treatment success as it is associated to privileged oncologic outcome.
- Conditions
- Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III, Distant Metastasis
- Trial name
- NCT05495308
- Testing
- neoadjuvant treatment
- Where
- Spain
- Volunteers
- 4 people
- Sponsor
- Hospital San Carlos, Madrid
Colorectal (Colon or Rectal) Cancer
TREM-1 - a New Marker of Serious Infectious Complications in Colorectal Surgery?
The aim of this study is to investigate the potential use of soluble TREM-1 (sTREM-1) to predict serious infectious complications in patients undergoing laparoscopic colorectal surgery.
- Trial name
- NCT05933408
- Testing
- TREM-1
- Where
- Poland
- Volunteers
- 64 people
- Sponsor
- Jagiellonian University
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006115
- Testing
- FOLFIRI regimen, FOLFOX regimen, fluorouracil
- Where
- 16 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Breast Cancer, Colorectal Cancer
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
RATIONALE: Printed educational materials, such as the Facing Forward Series: Life After Cancer Treatment manual, may help make the transition from cancer patient to cancer survivor easier in patients who are finishing treatment…
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Malignant Mesothelioma
- Trial name
- NCT00372840
- Testing
- educational intervention, psychosocial assessment and care, quality-of-life assessment
- Where
- United States
- Volunteers
- 340 people
- Sponsor
- Fox Chase Cancer Center
Rectal Cancer
Assessment of Symptoms and Consequences of Coloanal Continuity Reconstruction
This study is a prospective, monocentric study whose aim is to assess the quality of life for patients who underwent a coloanal continuity reconstruction and to understand the functional issues they encounter.
- Trial name
- QUALIPRO (NCT03292289)
- Testing
- Pre- and post-operative consultation, Stomatherapy consultation, Questionnaires
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Centre Oscar Lambret
Bladder Carcinoma, Ureter Carcinoma
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors.
- Conditions
- Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
- Trial name
- ORACLE (NCT05059444)
- Testing
- Guardant Reveal
- Where
- 57 sites in United States, France and 3 more
- Volunteers
- 2,285 people
- Sponsor
- Guardant Health, Inc.
Anal, Colon, and Rectal Cancers, Colorectal Neoplasms
Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer
To determine the maximum tolerated dose of Vandetanib with a current standard first-line chemotherapy regimen, capecitabine and oxaliplatin without and then with bevacizumab for the first line treatment of metastatic colorectal…
- Conditions
- Anal, Colon, and Rectal Cancers, Colorectal Neoplasms, Colon/Rectal Cancer
- Trial name
- NCT00532909
- Testing
- Vandetanib, Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Branimir Sikic
Locally Advanced Rectal Cancer With Liver Metastases
SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases
To enhance the treatment efficacy of rectal cancer liver metastasis through a multidisciplinary approach of radiotherapy, immunotherapy, and chemotherapy, and to provide a new direction for the combination treatment strategy.
- Trial name
- NCT06787183
- Testing
- Short course radiotherapy, Capecitabine, Oxaliplatin
- Where
- 2 sites in China
- Volunteers
- 42 people
- Sponsor
- Fujian Cancer Hospital